ALDENSTROM'S macroglobulinemia (WM) ac- counts for approximately 2% of hematologic cancers and affects approximately 1,500 Americans each year. The disease is more frequent among older persons and there may be a genetic predisposition, as suggested by family clusters."' The original description of WM focused on bone marrow infiltration by plasmacytoid lymphocytes and a high level of circulating macroglobulin (IgM).3 Many aspects of the biology and clinical features of this disease were summarized r e ~e n t l y . ~, ~ This review focuses on recent advances in the pathogenesis of complications caused by the elevated IgM and on the treatment of macroglobulinemic lymphoma.
Irene Dogliotti, Cristina Jiménez, Marzia Varettoni, Dipti Talaulikar, Tina Bagratuni, Martina Ferrante, José J. Pérez, Daniela Drandi, Noemí Puig, Milena Gilestro, María García‐Álvarez, Roger G. Owen, Wojciech Jurczak, Alessandra Tedeschi, Véronique Leblond, Efstathios Kastritis, Marie José Kersten, Shirley D’Sa, Michal Kaščák, Wolfgang Willenbacher, Aldo M. Roccaro, Stéphanie Poulain, Pierre Morel, Charalampia Kyriakou, Falko Fend, Josephine M. I. Vos, Meletios A Dimopoulos, Christian Buske, Simone Ferrero, Ramón García‐Sánz
Irene Dogliotti, Cristina Jiménez, Marzia Varettoni, Dipti Talaulikar, Tina Bagratuni, Martina Ferrante, José J. Pérez, Daniela Drandi, Noemí Puig, Milena Gilestro, María García‐Álvarez, Roger G. Owen, Wojciech Jurczak, Alessandra Tedeschi, Véronique Leblond, Efstathios Kastritis, Marie José Kersten, Shirley D’Sa, Michal Kaščák, Wolfgang Willenbacher, Aldo M. Roccaro, Stéphanie Poulain, Pierre Morel,
Discussion(0)
No comments yet. Be the first to comment.